SUZHOU, China, Sept. 26, 2023 /PRNewswire/ -- WuXi Vaccines, a leading contract development and manufacturing organization (CDMO) focused on vaccine discovery, development, and manufacturing, has launched its first standalone vaccines CDMO site in Suzhou, China.

中国苏州，2023年9月26日/PRNewswire/-无锡疫苗公司是一家专注于疫苗发现，开发和制造的领先合同开发和制造组织（CDMO），已在中国苏州推出首个独立疫苗CDMO网站。

The opening will add drug substance and drug product capacity, with end-to-end services for diversified vaccines that will accelerate global clients' project timelines – from process development and drug product development to clinical-scale drug substance (DS) and small-to-medium sterile drug product (DP) manufacturing.

此次开放将增加原料药和药品的能力，为多样化疫苗提供端到端服务，加快全球客户的项目时间表-从工艺开发和药品开发到临床规模原料药（DS）和中小型无菌药品（DP）制造。

Its DS production area includes two cell culture lines and one purification line supporting DS production scales from 50L to 1,000L, while maintaining a reserved capacity for 2,000L production. The DP facility is equipped with an automatic vial washing, sterilizing, filling and capping line, which can support the clinical production of both liquid and lyophilized products..

其DS生产区包括两条细胞培养系和一条净化线，支持DS生产规模从50L到1000L，同时保持2000L生产的预留容量。DP设施配有自动小瓶清洗，灭菌，灌装和封盖管线，可支持液体和冻干产品的临床生产。。

Mr. Jian Dong, CEO of WuXi Vaccines, commented, 'We are very pleased with the opening at our first standalone vaccine CDMO site in China. This is a great achievement for our company as it allows us to significantly expand our services and capacities. We look forward to working with our global partners to advance their pipelines, with the ultimate goal of improving the well-being of people worldwide.'.

无锡疫苗首席执行官董健先生评论说：“我们对中国第一个独立疫苗CDMO网站的开放感到非常高兴。这对我们公司来说是一个巨大的成就，因为它使我们能够大大扩展我们的服务和能力。我们期待与全球合作伙伴合作，推进其管道发展，最终目标是改善全球人民的福祉。

The site currently employs 200 people and anticipates having more than 500 employees when it reaches full operation. The manufacturing of large-scale commercial lyophilized drug product in vials is expected to launch by the end of 2024.

该网站目前雇用200人，预计在全面运营时拥有500多名员工。预计到2024年底将在小瓶中制造大规模商业冻干药品。

The WuXi Vaccines facility in Dundalk, Ireland, recently achieved its notable milestone and will initiate Tech Transfer (TT). In addition, the facility has continued its commissioning qualification and validation (CQV) activities. The QC potency lab became operational in July 2020 and received its GMP certificate from the Ireland Health Products Regulatory Authority (HPRA) in July 2022.

位于爱尔兰邓达尔克的无锡疫苗设施最近实现了其显着的里程碑，并将启动技术转让（TT）。此外，该设施继续进行调试资格和验证（CQV）活动。QC效能实验室于2020年7月投入运营，并于2022年7月获得爱尔兰健康产品监管局（HPRA）的GMP证书。

Currently, over 160 employees are working at the WuXi Vaccines Ireland site..

目前，超过160名员工正在无锡疫苗爱尔兰工厂工作。。

About WuXi Vaccines

关于无锡疫苗

WuXi Vaccines is a leading contract development and manufacturing organization (CDMO) that focuses on vaccine development and manufacturing. It provides world-class, integrated development and manufacturing platforms to expedite partners' vaccines to the clinical stage and the market, regardless of the vaccine modality (i.e., protein, virus, VLP, DNA, mRNA/RNA).

无锡疫苗是一家专注于疫苗开发和制造的领先合同开发和制造组织（CDMO）。它提供世界一流的综合开发和制造平台，以将合作伙伴的疫苗加速到临床阶段和市场，无论疫苗形式（即蛋白质，病毒，VLP，DNA，mRNA/RNA）如何。

With its technical expertise, broad regulatory knowledge, premium quality system, advanced CMC development capabilities, multiple production platforms (mammalian, microbial), and extensive GMP manufacturing capacities, WuXi Vaccines provides an end-to-end service – from vaccine discovery and development to large-scale commercial production and distribution.

无锡疫苗凭借其技术专长，广泛的监管知识，优质的体系，先进的CMC开发能力，多种生产平台（哺乳动物，微生物）和广泛的GMP生产能力，提供端到端的服务-从疫苗发现和开发到大规模的商业生产和分销。

The company can enable global clients to deliver critical vaccines anywhere in the world, making it an essential partner in protecting public health..

该公司可以使全球客户在世界任何地方提供关键疫苗，使其成为保护公共卫生的重要合作伙伴。。

For more information, please visit https://wuxivaccines.com.

欲了解更多信息，请访问https://wuxivaccines.com.

WuXi Vaccines ContactsBusiness[email protected]

无锡疫苗联系人商业[电子邮件保护]

Media[email protected]

媒体[电子邮件保护]

SOURCE WuXi Vaccines

来源无锡疫苗